Valneva SE

The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the experimental Lyme disease vaccine candidate from Pfizer and French biotech Valneva, and will now begin its official review. The filing rests on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older in high-incidence Lyme disease locations across the US, Canada, and Europe, which reported efficacy of over 70% in reducing confirmed Lyme disease cases with no safety issues detected. The statistical picture was less clean than the headline number: the first prespecified analysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%, while a second prespecified analysis showed 74.8% efficacy and did meet that threshold. Under the 2020 partnership and license agreement, Pfizer holds exclusive rights to produce and commercialize the vaccine if approved, with Valneva benefiting as development partner; Valneva says PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development. Pfizer shares were essentially flat on the news, and hedge fund ownership stood at 83 funds in the second quarter of 2026, unchanged from the first quarter, while Valneva's hedge fund exposure rose to 4 funds from 1. MAA validation means the application meets the standards for the EMA to begin evaluating it, not that approval is near or guaranteed, and formal reviews of this nature often take many months to complete.

Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. These milestones highlight Pfizer's role in infectious disease prevention, with the Lyme vaccine potentially becoming a key proof point for its pipeline. However, unresolved legal and pricing pressures, including the Depo Provera settlement program, remain overhangs. Pfizer's narrative projects $54.9 billion in revenue and $9.2 billion in earnings by 2029, implying a 4.6% yearly revenue decline and a $1.7 billion earnings increase from $7.5 billion today, yielding a $29.19 fair value, a 4% upside to its current price. Some analysts assume revenue could fall to about US$50.6 billion by 2029, reinforcing concerns that pipeline wins may not fully offset pricing pressure and patent losses.

Pfizer and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405, initiating the regulatory assessment process for what could become a first-in-class vaccine for the disease in North America and Europe. The application is backed by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This development is part of Pfizer's broader strategy to address widespread infectious diseases, complementing its existing vaccine portfolio. Investors should monitor the EMA's review milestones, including committee opinions and formal decisions expected into 2027, as well as any disclosures on manufacturing readiness and uptake expectations for the vaccine.

The European Medicines Agency has validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405, beginning its assessment of the submission. The application is based on efficacy of more than 70% observed in the Phase 3 VALOR trial, which enrolled 9,437 participants aged five and older across the U.S., Canada, and Europe, with no safety concerns identified. Pfizer's Chief Vaccines Officer Annaliesa Anderson said the vaccine could be the first of its kind in Europe, where Lyme disease affects more than 100,000 people annually and over 200 million live in risk areas. Valneva CEO Thomas Lingelbach called the acceptance a major milestone for the collaboration established in April 2020, under which Pfizer will exclusively manufacture and commercialize the vaccine if approved.